InteRNA, Radboud University Collaborate on miRNA Rx for Prostate Cancer

The arrangement will take advantage of InteRNA's proprietary lentiviral-based miRNA over-expression library, according to the partners.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.